Shilpa Medicare Limited, established in 1987, is a prominent pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and formulations, with a strong focus on oncology. Headquartered in Raichur, Karnataka, it serves regulated markets like the USA, Europe, and Japan, providing over 30 oncology APIs, including key drugs like Capecitabine and Gemcitabine Hydrochloride. The company's portfolio also includes non-oncology APIs and a variety of products such as Ambroxol and Tranexamic Acid.
Expanding its global footprint, Shilpa Medicare has incorporated several subsidiaries, including Shilpa Pharma Inc. in the USA, and engaged in strategic partnerships, such as its collaboration with Dr. Reddy's Laboratories for the Sputnik V vaccine. The company continues to innovate, launching new products in oncology and non-oncology sectors, including the first Indian branded generic of Ibrutinib. Additionally, it has invested in R&D capabilities with new centers for polymer and peptide research, while forming various subsidiaries to enhance its drug development and manufacturing operations.
